HCPLive
NOVEMBER 26, 2024
A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.
Becker's Hospital Review - Cardiology
NOVEMBER 26, 2024
An Atlanta-based Emory University Hospital team became the first in the U.S. to perform a surgical implantation of magnetically levitated ventricular assist device.
HCPLive
NOVEMBER 26, 2024
The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.
Med Page Today
NOVEMBER 26, 2024
(MedPage Today) -- Nearly half of participants in a weight-loss program who consumed alcohol at baseline began drinking less after adding an obesity drug into their weight-management regimen, a cohort study indicated. Among the 7,491 participants.
Science Daily - Heart Disease
NOVEMBER 26, 2024
You may have heard sleep described as something of a magic pill for the body. With the right amount, timing, and quality, it can work wonders -- strengthen the immune system, improve blood sugar, even decrease the risk of heart attacks and strokes. Sleep differences have been reported for some time in men and women, but it is not well known whether the characteristics of sleep serve different functions in one gender over the other, especially as it relates to the heart.
HCPLive
NOVEMBER 26, 2024
A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.
Science Daily - Heart Disease
NOVEMBER 26, 2024
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease -- aortic stenosis (AS).
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Science Daily - Heart Disease
NOVEMBER 26, 2024
Routine screening to detect risk factors for heart disease dropped sharply during the COVID-19 pandemic in England, and some key measurements, such as blood pressure readings, may still lag behind pre-pandemic levels, according to a new study.
Frontiers in Cardiovascular Medicine
NOVEMBER 26, 2024
BackgroundVentricular fibrillation (VF) is the deadliest arrhythmia, often caused by myocardial ischaemia. VF patients require urgent intervention planned quickly and non-invasively. However, the accuracy with which electrocardiographic (ECG) markers reflect the underlying arrhythmic substrate is unknown.MethodsWe analysed how ECG metrics reflect the fibrillatory dynamics of electrical excitation and ischaemic substrate.
Med Page Today
NOVEMBER 26, 2024
(MedPage Today) -- Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed. Cardiovascular risk and obesity had the strongest relationship with lower gray matter volume in men between.
Frontiers in Cardiovascular Medicine
NOVEMBER 26, 2024
Cardiovascular disease (CVD) is responsible for approximately 30% of annual global mortality rates, yet existing treatments for this condition are considered less than ideal. Despite being previously overlooked, lactate, a byproduct of glycolysis, is now acknowledged for its crucial role in the cellular functions of the cardiovascular system. Recent studies have shown that lactate influences the proliferation, differentiation, and activation of immune cells through its modulation of post-transla
Med Page Today
NOVEMBER 26, 2024
(MedPage Today) -- The American Heart Association said that hunters should be advised that physical exertion, colder temperatures, and the thrill of the hunt can put them at risk for heart attack or stroke. Merck announced positive topline results.
Becker's Hospital Review - Cardiology
NOVEMBER 26, 2024
GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.
Frontiers in Cardiovascular Medicine
NOVEMBER 26, 2024
ObjectivesThe bicuspid aortic valve (BAV) is the most common congenital heart defect. Patients with BAV frequently develop aortopathy, which depends on the dysfunction and morphotype of the BAV.AimThe aim of our study was to compare the echocardiography and cardiac magnetic resonance (CMR) findings in BAV patients, and to define the risks of BAV dysfunction and aortopathy.MethodsThe retrospective study included 50 patients (68% male) with BAV, with an average age of 13.6 ± 3.9 years, who underwe
HCPLive
NOVEMBER 26, 2024
Vivek Kaul, MD, discusses the benefits of using a stool DNA test for colorectal cancer screening, emphasizing its sensitivity, guideline recommendations, and its potential to reduce the screening burden for patients, as well as explaining the test's mechanism of action.
American College of Cardiology
NOVEMBER 26, 2024
The following are key points to remember from a 2024 updated international consensus statement on platelet function and genetic testing in percutaneous coronary intervention (PCI).
HCPLive
NOVEMBER 26, 2024
Hirschfield describes the need for therapies that address itch in PBC and explains what linerixibat, an IBAT inhibitor, may offer for pruritus.
HeartRhythm
NOVEMBER 26, 2024
A 70-year-old male underwent an electrophysiologic (EP) study for episodic palpitations. Baseline HV interval was 54 msec. Atrial extra stimulus testing induced a short- RP tachycardia initiated by prolongation of the AH interval. The response of the tachycardia to ventricular overdrive pacing (VOP) from the right ventricular (RV) apex is shown in figure 1A and the response to atrial overdrive pacing (AOP) is shown in figure 1B.
HCPLive
NOVEMBER 26, 2024
In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.
HeartRhythm
NOVEMBER 26, 2024
The cause of sudden cardiac arrest remains undefined in approximately 5% of patients, the latter receiving the diagnosis of ‘idiopathic ventricular fibrillation’ (IVF). Unraveling the mechanisms underlying the arrest is a clinical need for these often young patients who may be negatively impacted by uncertainties about their prognosis, including the risk for recurrences.1 By definition, IVF patients lack specific structural abnormalities.
HCPLive
NOVEMBER 26, 2024
The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.
HeartRhythm
NOVEMBER 26, 2024
Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor, representing the first disease-specific treatment for obstructive hypertrophic cardiomyopathy (HCM) that targets the core pathophysiological mechanism of this condition. Clinical evidence supports its efficacy in improving symptoms, cardiac function and remodeling, thereby supplementing established treatment regimes.
HCPLive
NOVEMBER 26, 2024
Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.
HeartRhythm
NOVEMBER 26, 2024
Atriofascicular fibers (AFF) are rare accessory pathways that have higher recurrence rates after ablation due to either failure to identify AFF (M) potentials and/or mechanical termination with contact.
HCPLive
NOVEMBER 26, 2024
Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.
HeartRhythm
NOVEMBER 26, 2024
Hematuria is common in patients with atrial fibrillation (AF) on oral anticoagulants (OAC). However, risks of incident genitourinary (GU) malignancy and detailed etiologies of hematuria have not been well studied.
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. Abstract Aims Mineralocorticoid receptor antagonists (MRA) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but are underused.
Frontiers in Cardiovascular Medicine
NOVEMBER 26, 2024
Cardio Vascular risk prevention in Germany has a gap between the ages of 20 and 30 years. We established a program for risk group identification in students and analyzed the screenings according to the ACCF/AHA Stages and NYHA functional classification. In a cross-sectional design, 596 participants completed a sports medical and motor performance check-up.
American College of Cardiology
NOVEMBER 26, 2024
What are the outcomes of patients referred for ventricular tachycardia (VT) ablation according to left ventricular ejection fraction (LVEF), tolerance of VT, and acute ablation outcome?
Dr. S. Venkatesan MD
NOVEMBER 26, 2024
Right from the days we entered medical schools, severe mitral stenosis was defined by less than 1 cm² MVO by echocardiography. It has been sacredly followed in most countries where RHD is prevalent. But, as western data (often derived with eastern patients) redefined the cut off for severe MS to 1.5 cm² in recent years ,Many of us are amused, rather confused.
American College of Cardiology
NOVEMBER 26, 2024
Use of intravascular lithotripsy (IVL) for the treatment of in-stent restenosis (ISR), although off-label, may be safe and feasible, according to a study reviewing data from the ACC's CathPCI Registry published in JACC: Cardiovascular Interventions.
The American Journal of Cardiology
NOVEMBER 26, 2024
Publication date: Available online 26 November 2024 Source: The American Journal of Cardiology Author(s): Silvio Nunes Augusto, Yuping Wu, Thanat Chaikijurajai, Stanley L. Hazen, W. H.
American College of Cardiology
NOVEMBER 26, 2024
In this interview, Thomas H. Marwick, MD, PhD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Takeaways from 2024 in Cardiovascular (CV) Imaging. Dr. Marwick discusses the SCOT-HEART trial, patient-echo reports augmented by AI, tricuspid valve regurgitation, and more.
HCPLive
NOVEMBER 26, 2024
Conaghan discussed findings from a phase 2 trial at the ACR 2024 Convergence.
American College of Cardiology
NOVEMBER 26, 2024
The U.S. Food and Drug Administration (FDA) has approved acoramidis as a treatment to help reduce cardiovascular death and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
HCPLive
NOVEMBER 26, 2024
Patients in the anifrolumab arm also had lower rates of damage accrual.
HeartRhythm
NOVEMBER 26, 2024
Few data are available on the clinical course of patients with supraventricular tachycardia (SVT).
Expert insights. Personalized for you.
103 
Let's personalize your content